Phase 2 trial observes effects of oral ALZ-801 on biomarkers, hippocampal volume, and cognition in APOE4 carriers with early Alzheimer's disease, highlighting potential disease modification.
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer's disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments.
No takes yet. Share an insight, caveat, or question.
Hey et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: